The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung. / Roed, H; Vindeløv, Lars; Christensen, I J; Spang-Thomsen, M; Hansen, H H.

I: Cancer Chemotherapy and Pharmacology, Bind 19, Nr. 1, 1987, s. 16-20.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Roed, H, Vindeløv, L, Christensen, IJ, Spang-Thomsen, M & Hansen, HH 1987, 'The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung', Cancer Chemotherapy and Pharmacology, bind 19, nr. 1, s. 16-20.

APA

Roed, H., Vindeløv, L., Christensen, I. J., Spang-Thomsen, M., & Hansen, H. H. (1987). The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung. Cancer Chemotherapy and Pharmacology, 19(1), 16-20.

Vancouver

Roed H, Vindeløv L, Christensen IJ, Spang-Thomsen M, Hansen HH. The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung. Cancer Chemotherapy and Pharmacology. 1987;19(1):16-20.

Author

Roed, H ; Vindeløv, Lars ; Christensen, I J ; Spang-Thomsen, M ; Hansen, H H. / The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung. I: Cancer Chemotherapy and Pharmacology. 1987 ; Bind 19, Nr. 1. s. 16-20.

Bibtex

@article{bb82d930654f11de8bc9000ea68e967b,
title = "The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung",
abstract = "To determine whether there is any difference between the two epipodophyllotoxin derivatives etoposide and teniposide in their therapeutic effect in small cell carcinoma of the lung (SCCL), they were compared against five human SCCL cell lines in vitro. When the two were compared at equimolar concentrations teniposide was found to be 8-10 times more potent than etoposide, both with 1-h incubation and with continuous incubation in a clonogenic assay and in inducing cell cycle perturbations monitored by flow cytometry. Published pharmacokinetic data suggest that this potency difference is not accompanied by an equivalent increase in toxicity. The concentrations used for the 1-h incubation were about 100-fold the concentrations used in the experiments with continuous incubation to obtain the same degree of cell kill for both drugs. This suggests that they should be given according to a continuous rather than an intermittent schedule.",
author = "H Roed and Lars Vindel{\o}v and Christensen, {I J} and M Spang-Thomsen and Hansen, {H H}",
note = "Keywords: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Line; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Lung Neoplasms; Podophyllotoxin; Teniposide",
year = "1987",
language = "English",
volume = "19",
pages = "16--20",
journal = "Cancer Chemotherapy and Pharmacology, Supplement",
issn = "0943-9404",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung

AU - Roed, H

AU - Vindeløv, Lars

AU - Christensen, I J

AU - Spang-Thomsen, M

AU - Hansen, H H

N1 - Keywords: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Line; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Lung Neoplasms; Podophyllotoxin; Teniposide

PY - 1987

Y1 - 1987

N2 - To determine whether there is any difference between the two epipodophyllotoxin derivatives etoposide and teniposide in their therapeutic effect in small cell carcinoma of the lung (SCCL), they were compared against five human SCCL cell lines in vitro. When the two were compared at equimolar concentrations teniposide was found to be 8-10 times more potent than etoposide, both with 1-h incubation and with continuous incubation in a clonogenic assay and in inducing cell cycle perturbations monitored by flow cytometry. Published pharmacokinetic data suggest that this potency difference is not accompanied by an equivalent increase in toxicity. The concentrations used for the 1-h incubation were about 100-fold the concentrations used in the experiments with continuous incubation to obtain the same degree of cell kill for both drugs. This suggests that they should be given according to a continuous rather than an intermittent schedule.

AB - To determine whether there is any difference between the two epipodophyllotoxin derivatives etoposide and teniposide in their therapeutic effect in small cell carcinoma of the lung (SCCL), they were compared against five human SCCL cell lines in vitro. When the two were compared at equimolar concentrations teniposide was found to be 8-10 times more potent than etoposide, both with 1-h incubation and with continuous incubation in a clonogenic assay and in inducing cell cycle perturbations monitored by flow cytometry. Published pharmacokinetic data suggest that this potency difference is not accompanied by an equivalent increase in toxicity. The concentrations used for the 1-h incubation were about 100-fold the concentrations used in the experiments with continuous incubation to obtain the same degree of cell kill for both drugs. This suggests that they should be given according to a continuous rather than an intermittent schedule.

M3 - Journal article

C2 - 3815721

VL - 19

SP - 16

EP - 20

JO - Cancer Chemotherapy and Pharmacology, Supplement

JF - Cancer Chemotherapy and Pharmacology, Supplement

SN - 0943-9404

IS - 1

ER -

ID: 12871064